It looks like your browser is outdated. For the best experience, please consider updating to the latest version or switching to another browser (Firefox, Chrome, Safari).

This page is not supported in mobiles. Please view it in the desktop version.

BioPharma Solutions BioPharma Solutions
Sterile Contract Manufacturing

Halle/Westfalen, Germany

Print

Expansion Complete - See Your Future Today!

Cancer incidence is on the rise and cytotoxic therapies continue to be at the center of oncology treatment programs. Through this latest expansion in Halle, Germany, Baxter BioPharma Solutions will continue to support pharmaceutical companies' efforts to address patient needs worldwide.

Contact your Baxter BioPharma Solutions representative to schedule a tour of our state-of-the-art addition.

About the Expansion:

Pharma Production Building E (PPE) is Baxter's latest major expansion in Halle. The expanded facility is dedicated to contract manufacturing of oncology products. Our long-time experience in sterile manufacturing has been utilized by our engineers to design a building with a strong focus on our customers and their need for flexibility, product quality and high yield.

Transparency is one of the key features of the new building. Glass was used to enhance visibility of the manufacturing lines and processes. This "facility made out of glass" concept allows you to view the actual critical manufacturing processes in a clean room class A while conveniently standing in a clean room class D.

Key Features of the Facility Expansion

Facility Expansion Facility Expansion
  • 1800 sqm footprint with 2 independent manufacturing lines designed for oncology drugs
  • Innovative fill line layout combining isolator technology and Restricted Access Barrier Systems (RABS)
  • Optimized process layout - possible interventions during filling have been separated from critical aseptic areas by design
  • Two alternative filling principles provide significant filling flexibility. Peristaltic pumps as well as rotary piston pumps can be chosen based on the characteristics of the product
  • High yield: potential losses on the filling line are reduced to a minimum by several optimizations like integration of inline scales which allow for 100% fill weight checks during filling Critical processing steps like stopper clearance and capping are controlled by state-of-the-art camera inspections
  • Small-scale line, "E2", features a flexible compounding area, vial filling line and a 17 m2 freezer-dryer
  • Large scale line, "E1", with its dedicated compounding area, is specialized for large-scale formulation and and offers two 40 m2 freeze-dryers
  • Lyophilization & liquid filling of vials from 2 mL up to 100 mL vial size
  • Temperature sensitive, light sensitive and oxygen sensitive products can be processed on the filling lines
  • Innovative disinfection system allows reduction of process time by several hours compared to standard disinfection programs using vaporized hydrogen peroxide
FOYA
Capacity Expansion